Abstract
One possible origin of the type I hypersensitivity reaction is reaction of drugs such as acetylsalicylic acid and its metabolites being complexed with human serum albumin. Albumin, being transporting molecule abundant in blood plasma is able to bind large array of ligands varying from small single carbon particles to long hydrophobic tailed lipidic acids (e.g. myristic acid). This non specificity is possible because of multi domain scaffold and large flexibility of inter-domain loops, which results in serious reorientation of domains. Hypothesis that acetylsalicylic acid metabolites may play indirect role in activation of allergic reaction has been tested. Binding of acetylsalicylic acid metabolites in intra-domain space causes significant increase of liability of domains IIIA and IIIB. One of metabolites, salicyluric acid, once is bound causes distortion and partial unfolding of helices in domains IA, IIB and IIIB. Changed are both directions and amplitude of relative motions as well as intra-domain distances. In result albumin is able to cross-link of adjacent IgE receptors which subsequently starts allergic reaction.
Keywords: Acetylsalicylic acid, drug hypersensitivity, molecular docking, molecular dynamics, cross-linking
Current Drug Metabolism
Title: Serum Albumin Complexation of Acetylsalicylic Acid Metabolites
Volume: 10 Issue: 5
Author(s): Wiktor Jurkowski, Grzegorz Porebski, Krystyna Obtulowicz and Irena Roterman
Affiliation:
Keywords: Acetylsalicylic acid, drug hypersensitivity, molecular docking, molecular dynamics, cross-linking
Abstract: One possible origin of the type I hypersensitivity reaction is reaction of drugs such as acetylsalicylic acid and its metabolites being complexed with human serum albumin. Albumin, being transporting molecule abundant in blood plasma is able to bind large array of ligands varying from small single carbon particles to long hydrophobic tailed lipidic acids (e.g. myristic acid). This non specificity is possible because of multi domain scaffold and large flexibility of inter-domain loops, which results in serious reorientation of domains. Hypothesis that acetylsalicylic acid metabolites may play indirect role in activation of allergic reaction has been tested. Binding of acetylsalicylic acid metabolites in intra-domain space causes significant increase of liability of domains IIIA and IIIB. One of metabolites, salicyluric acid, once is bound causes distortion and partial unfolding of helices in domains IA, IIB and IIIB. Changed are both directions and amplitude of relative motions as well as intra-domain distances. In result albumin is able to cross-link of adjacent IgE receptors which subsequently starts allergic reaction.
Export Options
About this article
Cite this article as:
Jurkowski Wiktor, Porebski Grzegorz, Obtulowicz Krystyna and Roterman Irena, Serum Albumin Complexation of Acetylsalicylic Acid Metabolites, Current Drug Metabolism 2009; 10 (5) . https://dx.doi.org/10.2174/138920009788897984
DOI https://dx.doi.org/10.2174/138920009788897984 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacogenomics of Asthma
Current Pharmaceutical Design Prospectives of Antihypertensive Nano-ceuticals as Alternative Therapeutics
Current Drug Targets Neuroprotective Methodologies of Co-Enzyme Q10 Mediated Brain Hemorrhagic Treatment: Clinical and Pre-Clinical Findings
CNS & Neurological Disorders - Drug Targets Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery Renin-angiotensin System Blockade at the Level of the Angiotensin Converting Enzyme or the Angiotensin Type-1 Receptor: Similarities and Differences
Current Topics in Medicinal Chemistry Specific Aspects of Drug Hypersensitivity in Children
Current Pharmaceutical Design Clinical Experience with the Use of Angiotensin Receptor Blockers in Patients with Cardiovascular, Cerebrovascular and Renal Diseases
Current Clinical Pharmacology Pharmacological, Immunological, and Gene Targeting of the Renin-Angiotensin System for Treatment of Cardiovascular Disease
Current Pharmaceutical Design More Effective DPP4 Inhibitors as Antidiabetics Based on Sitagliptin Applied QSAR and Clinical Methods
Current Computer-Aided Drug Design Antiepileptic Drug-Induced Hypersensitivity Syndrome Reactions
Current Drug Safety Peptide and Non-peptide Antagonists Targeting Endothelin Receptors in Physiology and Pathology
Current Pharmaceutical Design Successful Desensitization of Three Patients with Hypersensitivity Reactions to Omalizumab
Current Drug Safety A Review of Current Knowledge of the Complement System and the Therapeutic Opportunities in Inflammatory Arthritis
Current Medicinal Chemistry The Shift in the “Paradigm” of the Pharmacology of Hypertension
Current Topics in Medicinal Chemistry The Role of Anti-Inflammatory Drugs in Respiratory Diseases - Pirfenidone, Penicillamine, Chloroquine and Chlorambucil
Current Respiratory Medicine Reviews The Complement Cascade: New Avenues in Stroke Therapy
Current Vascular Pharmacology Twenty Years of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: Time to Reevaluate their Toxicity
Current Medicinal Chemistry Advances in Peptide Pharmaceuticals
Current Pharmaceutical Biotechnology Novel Possible Pharmaceutical Research Tools: Stem Cells, Gene Delivery and their Combination
Current Pharmaceutical Design Editorial [Hot topic: Recent Progress in Cancer Therapeutics (Guest Editor: Kurt S. Zaenker)]
Current Molecular Medicine